Bioventures 2014 L.P. Mpm Sells 61,640 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 61,640 shares of the stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $0.93, for a total value of $57,325.20. Following the completion of the sale, the insider directly owned 5,538,600 shares of the company’s stock, valued at approximately $5,150,898. The trade was a 1.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Monday, November 17th, Bioventures 2014 L.P. Mpm sold 57,061 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total transaction of $54,207.95.
• On Thursday, November 13th, Bioventures 2014 L.P. Mpm sold 90,951 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $89,131.98.
• On Wednesday, November 12th, Bioventures 2014 L.P. Mpm sold 40,669 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.09, for a total transaction of $44,329.21.
• On Tuesday, November 11th, Bioventures 2014 L.P. Mpm sold 55,810 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $63,623.40.
• On Monday, November 10th, Bioventures 2014 L.P. Mpm sold 48,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.18, for a total transaction of $57,312.60.
• On Friday, November 7th, Bioventures 2014 L.P. Mpm sold 68,480 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.11, for a total transaction of $76,012.80.
• On Thursday, November 6th, Bioventures 2014 L.P. Mpm sold 54,452 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total value of $65,886.92.
• On Wednesday, November 5th, Bioventures 2014 L.P. Mpm sold 47,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $58,499.00.
• On Tuesday, November 4th, Bioventures 2014 L.P. Mpm sold 140,488 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $171,395.36.
• On Monday, November 3rd, Bioventures 2014 L.P. Mpm sold 94,063 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total value of $121,341.27.

Werewolf Therapeutics Stock Performance

Shares of HOWL stock traded up $0.00 during trading on Monday, reaching $0.92. 519,418 shares of the company’s stock were exchanged, compared to its average volume of 503,244. Werewolf Therapeutics, Inc. has a twelve month low of $0.60 and a twelve month high of $2.38. The firm’s fifty day moving average price is $1.57 and its 200-day moving average price is $1.34. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $44.63 million, a PE ratio of -0.57 and a beta of 0.72.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. As a group, sell-side analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics during the second quarter valued at $409,000. Citadel Advisors LLC bought a new stake in shares of Werewolf Therapeutics in the third quarter worth $304,000. Vanguard Group Inc. increased its holdings in Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares during the period. Marshall Wace LLP bought a new position in Werewolf Therapeutics during the 2nd quarter worth $113,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Werewolf Therapeutics during the 2nd quarter worth about $92,000. 64.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on HOWL. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Bank of America lowered their target price on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, August 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. JMP Securities decreased their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.